These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 2697396

  • 1. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
    De Witte T, Muus P, De Pauw B, Haanen C.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
    [Abstract] [Full Text] [Related]

  • 2. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
    De Witte T, Muus P, De Pauw B, Haanen C.
    Cancer; 1990 Sep 01; 66(5):831-7. PubMed ID: 2386911
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).
    De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J.
    Bone Marrow Transplant; 1989 Dec 01; 4 Suppl 3():38-9. PubMed ID: 2697398
    [Abstract] [Full Text] [Related]

  • 4. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M.
    Leukemia; 1995 Nov 01; 9(11):1805-11. PubMed ID: 7475266
    [Abstract] [Full Text] [Related]

  • 5. [Intensive chemotherapy in myelodysplastic syndromes].
    Dombret H.
    Pathol Biol (Paris); 1997 Oct 01; 45(8):627-35. PubMed ID: 9569928
    [Abstract] [Full Text] [Related]

  • 6. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M.
    Int J Hematol; 2000 Aug 01; 72(2):139-50. PubMed ID: 11039661
    [Abstract] [Full Text] [Related]

  • 7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 01; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.
    Cancer; 2006 Mar 01; 106(5):1099-109. PubMed ID: 16435387
    [Abstract] [Full Text] [Related]

  • 9. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Kuriya S, Murai K, Miyairi Y, Utsugisawa T, Narigasawa Y, Ito T, Shimosegawa K, Ishida Y.
    Cancer; 1996 Aug 01; 78(3):422-6. PubMed ID: 8697386
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 01; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 11. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
    Hasle H, Kerndrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N, Jacobsen BB.
    Leukemia; 1996 Aug 01; 10(8):1269-73. PubMed ID: 8709630
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E.
    Cancer; 2003 Mar 01; 97(5):1234-41. PubMed ID: 12599230
    [Abstract] [Full Text] [Related]

  • 13. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Mar 01; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J.
    Bone Marrow Transplant; 1998 Feb 01; 21(3):255-61. PubMed ID: 9489648
    [Abstract] [Full Text] [Related]

  • 15. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Feb 01; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

  • 16. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM, de Witte T, de Pauw BE, Haanen C.
    Neth J Med; 1990 Feb 01; 36(1-2):19-24. PubMed ID: 2314517
    [Abstract] [Full Text] [Related]

  • 17. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul 01; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

  • 18. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM.
    J Clin Oncol; 2015 Nov 01; 33(31):3641-9. PubMed ID: 26304885
    [Abstract] [Full Text] [Related]

  • 19. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E.
    Cancer; 2004 Feb 01; 100(3):581-9. PubMed ID: 14745876
    [Abstract] [Full Text] [Related]

  • 20. [Clinical significance of micromegakaryocytes in de novo AML].
    Kobayashi S, Seki K, Katayama N, Akiba C, Yamamoto T, Sakai K, Yamaguchi M, Maruta A, Noguchi T, Ogawa K.
    Rinsho Ketsueki; 1993 Mar 01; 34(3):313-20. PubMed ID: 8479083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.